 NEW YORK, Sept. 09, 2022 GLOBE NEWSWIRE -- Immunovant, Inc. Nasdaq: IMVT, a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022. 